Concord Biotech Limited’s Initial Public Offering to open on Friday, 4th August, 2023, sets price band at ₹705 to ₹741 per Equity Share
Mr. Lalit Sethi, CFO, Mr. Sudhir Vaid, Chairman & CEO & Mr. Ankur Vaid, Joint MD & CEO, Concord Biotech Limited. RHP Link: https://www.sebi.gov.in/filings/public-issues/jul-2023/concord-biotech-limited-rhp_74629.html Ahmedabad-based Concord Biotech Limited, is country-based biotechnology company and is one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022 has fixed the price band at ₹705 to ₹741 per Equity Share for its maiden public offer. The initial public offering (“IPO” or “Offer”) of the Company will open on Friday, 4th August, 2023, for subscription and closes on Tuesday, 8th August, 2023. Investors can bid for a minimum of 20 Equity Shares and in multiples of 20 Equity Shares thereafter. The Public Issue of face value of ₹1 per Equity Share is entirely an Offer for Sale (OFS) up to 20.92 million shares by Helix Investment Holdings Pte. Limited....